Plate Nº 90 · recorded November 12, 2026
Neuroscience & MindReported finding
Brain scans reveal shrinkage in treatment-resistant schizophrenia
A six-country study of over 1,200 brain scans links treatment-resistant schizophrenia to reduced hippocampus volume — a step toward earlier diagnosis, but not a clinical test yet.
By Marcus Bennett4 min read713 words
In brief
- Up to 60 percent of schizophrenia patients do not respond adequately to standard antipsychotics.
- The study analyzed scans from 1,200+ individuals at seven sites in six countries.
- Treatment-resistant patients showed reduced hippocampus volume and reduced surface area in the left superior frontal gyrus.
- Medication dosage did not statistically explain the hippocampus or frontal gyrus differences.
- The brain measurements could not yet reliably distinguish individual treatment-resistant patients.
People with treatment-resistant schizophrenia have measurably less tissue in the hippocampus, the putamen, and a region near the front of the brain called the left superior frontal gyrus, according to a study published in the journal Molecular Psychiatry. The findings come from brain scans of more than 1,200 individuals across seven sites in six countries, and they point toward a future in which doctors could identify hard-to-treat patients before months of failed drug trials erode their mental health.
Why does this matter for clinicians?
Up to 60 percent of schizophrenia patients get inadequate relief from standard antipsychotics, which work mainly by blocking dopamine receptors. The only approved drug for this group, clozapine, demands strict blood monitoring because of the risk of severe immune system complications — and even then, a substantial share of patients do not respond.
Today, treatment resistance is diagnosed only after a patient fails multiple antipsychotic trials, a trial-and-error process that can stretch across months or years while symptoms worsen. An objective biological marker would let clinicians skip that waiting period and start specialized care immediately.
For now, that marker does not exist in usable form. But the study narrows the search.
What did the researchers actually find?
A team led by Semra Etyemez, Kun Yang, and Akira Sawa at the Johns Hopkins University School of Medicine partnered with an international neuroimaging consortium. The dataset included 158 patients with treatment-resistant schizophrenia, 599 patients who responded to standard treatments, and 508 healthy individuals. Clinicians at each site classified patients using comprehensive clinical and medication records.
The researchers first ran a meta-analysis — a method that pools statistical results from independent datasets to spot overarching trends — comparing volumes of deep brain structures and the thickness and surface area of the brain's outer layer. They adjusted for age, sex, race, head size, and illness duration.
Three differences stood out in the treatment-resistant group:
- Reduced volume in both sides of the hippocampus, a seahorse-shaped structure deep in the brain essential for memory and learning.
- Reduced volume in the putamen, a round structure at the base of the brain involved in learning and motor control.
- Reduced surface area in the left superior frontal gyrus, a front-brain region involved in cognitive processing.
The team then ran a mega-analysis, pooling all raw scan data into a single unified dataset rather than combining statistical summaries, with the healthy volunteers establishing a baseline. It confirmed all three reductions.
The hippocampus and superior frontal gyrus showed a stepwise pattern: healthy individuals had the largest tissue volumes, treatment-responsive patients had smaller volumes, and treatment-resistant patients had the smallest. The putamen broke the pattern — it showed no statistical difference between treatment-resistant patients and healthy individuals, and it was actually larger in treatment-responsive patients than in controls.
Are the differences caused by the drugs?
Because patients had taken varying antipsychotic types and doses over varying periods, the researchers tested whether the anatomical changes were medication side effects. They correlated anatomical measurements with cumulative antipsychotic dosage and checked specifically for links with clozapine.
Medication dosage showed no statistically significant relationship with hippocampus size or superior frontal gyrus surface area, suggesting the shrinkage in those areas reflects the underlying biology of treatment-resistant schizophrenia rather than its treatment. The putamen showed a weak correlation with cumulative medication use, indicating drugs might slightly influence that structure.
What are the study's limits?
The participant pool, drawn from North America, Europe, and Asia, lacked African and Latino representation, so the team cannot yet confirm whether the differences hold across all populations. The treatment-responsive group may also contain individuals who will develop resistance later.
Most importantly for practitioners, the measurements cannot yet diagnose anyone individually. When researchers tested the predictive power of the brain measurements, their models could not reliably distinguish treatment-resistant patients from other schizophrenia patients one by one.
A clinically useful test will likely require combining brain imaging with other biological indicators, such as genetic profiles or metabolic markers. The full author list — spanning institutions across three continents — appears in the paper, "Brain structural abnormalities in treatment-resistant schizophrenia."
Smaller hippocampi track with treatment resistance, but they cannot yet predict it for a single patient sitting in your clinic.
via psypost.org (Source)
More from Marcus Bennett
Show full bio
News editor covering regulation, policy and their impact on general science news at SciBeat.
374 articles
Nearby plates
- Short-Acting Psychedelic Tested Against Major Depression in Phase IIa Trial
- MIT Points to Brain Circuit for Updating Beliefs in Schizophrenia
- McGill Launches Largest-Ever Psychedelics Study for Mental Health
- BIIB080 Phase 1b: Exploratory Results in Mild Alzheimer's
- Brain Scans Reveal How Depression Treatment Reshapes Neural Connections